We are initiating a clinical trial program to investigate our compounds for enhancing the immune system to kill cancer cells in conjunction with tumor vaccines. Galectin-3 is thought to play a key role in diminishing the ability of TIL to kill tumor cells and blocking the action of galectin-3 is believed to improve the efficacy of T lymphocytes in killing tumor cells, as demonstrated in preclinical studies.
We recently initiated a Phase 1/2 clinical trial of GM-CT-01 in combination with a tumor vaccine in patients with advanced melanoma, a deadly skin cancer. The trial is being conducted at three centers in Belgium and one in Luxembourg. The operational conduct of the trial is under the control of the Cancer Centre at the Cliniques Universitaires Saint-Luc and the Ludwig Institute for Cancer Research. The study has been initiated and the operations for beginning to enroll patients are underway. Positive results from this study could indicate that inhibiting the "Galectin Effect" could be an enabling technology for therapy in other tumor types.